<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="370">
  <stage>Registered</stage>
  <submitdate>5/06/2003</submitdate>
  <approvaldate>5/06/2003</approvaldate>
  <nctid>NCT00062257</nctid>
  <trial_identification>
    <studytitle>Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer</studytitle>
    <scientifictitle>A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CDR0000304669</secondaryid>
    <secondaryid>CTRG-G15/02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastric Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - irofulven

Treatment: drugs: irofulven


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed gastric adenocarcinoma

               -  Recurrent or metastatic disease

               -  Adenocarcinoma of the gastroesophageal junction eligible provided the majority of
                  tumor bulk is below the junction

          -  Measurable disease

               -  At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by
                  spiral CT scan

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  No active disseminated intravascular coagulation

        Hepatic

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST/ALT no greater than 2.5 times ULN (5 times ULN for patients with liver metastases)

          -  Alkaline phosphatase no greater than 5 times ULN

        Renal

          -  Creatinine no greater than 1.5 times ULN

        Cardiovascular

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No prior allergic reaction attributed to compounds of similar chemical or biological
             composition to irofulven

          -  No other malignancy within the past 5 years except adequately treated carcinoma in
             situ of the cervix or basal cell or squamous cell skin cancer

          -  No other uncontrolled concurrent illness that would preclude study participation

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  Must have central or peripherally inserted central catheter

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa

        Chemotherapy

          -  No prior chemotherapy for recurrent or metastatic disease

          -  Prior adjuvant or neoadjuvant chemotherapy allowed provided disease relapsed more than
             6 months after therapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy and recovered

        Surgery

          -  Not specified

        Other

          -  No other concurrent investigational or commercial agents or therapies for the
             malignancy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Sydney Cancer Centre at Royal Prince Alfred Hospital - Sydney</hospital>
    <postcode>2050 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin, New Territories</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Cancer Therapeutics Research Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy, such as irofulven, use different ways to stop tumor
      cells from dividing so they stop growing or die.

      PURPOSE: This phase II trial is studying how well irofulven works in treating patients with
      recurrent or metastatic gastric cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00062257</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Winnie Yeo</name>
      <address>Prince of Wales Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>